These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29156890)

  • 21. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
    Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
    J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2-positive breast cancer.
    Loibl S; Gianni L
    Lancet; 2017 Jun; 389(10087):2415-2429. PubMed ID: 27939064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pertuzumab for the treatment of metastatic breast cancer.
    Langdon SP; Cameron DA
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):907-18. PubMed ID: 23984893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
    Malenfant SJ; Eckmann KR; Barnett CM
    Pharmacotherapy; 2014 Jan; 34(1):60-71. PubMed ID: 23918291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
    Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
    Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pertuzumab: development beyond breast cancer.
    Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
    Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pertuzumab and solid tumors: perspectives].
    Barthélémy P; Leblanc J; Wendling F; Wissler MP; Bergerat JP
    Bull Cancer; 2014 Dec; 101(12):1114-21. PubMed ID: 25532690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in targeting HER2-positive breast cancer.
    Harbeck N
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):55-59. PubMed ID: 29194077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer.
    Ferrario C; Wong A; Gao T; Bouganim N; Aloyz R; Panasci LC
    J Chemother; 2011 Feb; 23(1):32-5. PubMed ID: 21482492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2017 Oct; 37(10):5623-5630. PubMed ID: 28982879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pertuzumab for the treatment of breast cancer: a safety review.
    Gao J; Swain SM
    Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci F; Le Tourneau C
    Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
    [No Abstract]   [Full Text] [Related]  

  • 36. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer.
    Walshe JM; Denduluri N; Berman AW; Rosing DR; Swain SM
    Clin Breast Cancer; 2006 Feb; 6(6):535-9. PubMed ID: 16595039
    [No Abstract]   [Full Text] [Related]  

  • 37. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Hou Y; Nitta H; Wei L; Banks PM; Portier B; Parwani AV; Li Z
    Breast Cancer Res Treat; 2017 Nov; 166(2):447-457. PubMed ID: 28799059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.